Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634510 | 0.86 | NPC1 (0.56) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL5101791 | 0.85 | KMT2A (0.60) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL5095610 | 0.85 | NPC1 (0.77) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL5090143 | 0.85 | NPC1 (0.55) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL6635814 | 0.84 | MEN1 (0.52) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL5095592 | 0.84 | MEN1 (0.78) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL6637587 | 0.83 | KMT2A (0.57) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL5096125 | 0.82 | MEN1 (0.61) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL5090132 | 0.82 | TRPV1 (0.56) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL5090202 | 0.82 | HDAC3 (0.63) | CTSAHDAC3HDAC1HDAC2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984967-B1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | IAF BIOCHEM INT (CA) | 2004-02-25 | — | — | EP | claimed |
| EP-1037633-B1 | ANTIVIRAL COMPOUNDS | IAF BIOCHEM INT (CA) | 2003-09-10 | — | — | EP | claimed |
| US-20010031765-A1 | Antiviral compounds | BIOCHEM PHARMA INC. | 2001-10-18 | — | — | US | claimed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | claimed |
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | GPC BIOTECH AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-0984967-B1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | IAF BIOCHEM INT (CA) | 2004-02-25 | — | — | EP | disclosed |
| EP-1037633-B1 | ANTIVIRAL COMPOUNDS | IAF BIOCHEM INT (CA) | 2003-09-10 | — | — | EP | disclosed |
| US-6534520-B2 | Antiviral compounds | BIOCHEM PHARMA INC. (CA) | 2003-03-18 | — | — | US | disclosed |
| US-20010031765-A1 | Antiviral compounds | BIOCHEM PHARMA INC. | 2001-10-18 | — | — | US | disclosed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | disclosed |
| CN-1283995-A | Antiviral compounds | IAF BIOCHEM INT (CA) | 2001-02-14 | — | — | CN | disclosed |
| EP-1037633-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC (CA) | 2000-09-27 | — | — | EP | disclosed |
| EP-0984967-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC (CA) | 2000-03-15 | — | — | EP | disclosed |
| US-5945431-A | VIRICIDE | BIOCHEM THERAPEUTICS INCORPORATED (CA) | 1999-08-31 | — | — | US | disclosed |
| WO-1999029318-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC. (CA) | 1999-06-17 | — | — | WO | disclosed |
| WO-1997034894-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC. (CA) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | ROCK2, ROCK1, RHOT2 | CTSA 3764/4885NPC1 637/4885RAB9A 2097/4885 |
| US-20010031765-A1 | Antiviral compounds | ZC3HAV1, IFNAR1, EIF2AK2 | CTSA 711/4885NPC1 1407/4885RAB9A 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.